[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR22C1039I2 - Polysaccharides capsulaires de streptococcus pneumoniae et conjugués de ceux-ci - Google Patents

Polysaccharides capsulaires de streptococcus pneumoniae et conjugués de ceux-ci

Info

Publication number
FR22C1039I2
FR22C1039I2 FR22C1039C FR22C1039C FR22C1039I2 FR 22C1039 I2 FR22C1039 I2 FR 22C1039I2 FR 22C1039 C FR22C1039 C FR 22C1039C FR 22C1039 C FR22C1039 C FR 22C1039C FR 22C1039 I2 FR22C1039 I2 FR 22C1039I2
Authority
FR
France
Prior art keywords
conjugate
streptococcus pneumoniae
capsular polysaccharides
capsular
polysaccharides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1039C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of FR22C1039I1 publication Critical patent/FR22C1039I1/fr
Application granted granted Critical
Publication of FR22C1039I2 publication Critical patent/FR22C1039I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Sustainable Development (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR22C1039C 2014-01-21 2022-07-28 Polysaccharides capsulaires de streptococcus pneumoniae et conjugués de ceux-ci Active FR22C1039I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461929598P 2014-01-21 2014-01-21
PCT/IB2015/050314 WO2015110940A2 (en) 2014-01-21 2015-01-15 Streptococcus pneumoniae capsular polysaccharides and conjugates thereof

Publications (2)

Publication Number Publication Date
FR22C1039I1 FR22C1039I1 (fr) 2022-09-09
FR22C1039I2 true FR22C1039I2 (fr) 2023-05-26

Family

ID=52630419

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1039C Active FR22C1039I2 (fr) 2014-01-21 2022-07-28 Polysaccharides capsulaires de streptococcus pneumoniae et conjugués de ceux-ci

Country Status (21)

Country Link
US (4) US10105431B2 (ru)
EP (2) EP3957321A3 (ru)
JP (4) JP6612260B2 (ru)
KR (2) KR102049826B1 (ru)
CN (2) CN112168957A (ru)
AU (2) AU2015208820B2 (ru)
BR (1) BR112016015835B1 (ru)
CA (1) CA2937184A1 (ru)
DK (1) DK3096783T3 (ru)
ES (1) ES2883343T3 (ru)
FR (1) FR22C1039I2 (ru)
HK (1) HK1223273A1 (ru)
HR (1) HRP20211337T1 (ru)
HU (1) HUE055408T2 (ru)
IL (5) IL283554B (ru)
MX (2) MX382438B (ru)
PL (1) PL3096783T3 (ru)
PT (1) PT3096783T (ru)
RU (1) RU2710393C2 (ru)
SI (1) SI3096783T1 (ru)
WO (1) WO2015110940A2 (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2937184A1 (en) 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PE20240927A1 (es) * 2015-07-21 2024-04-30 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
US10786561B2 (en) * 2015-11-20 2020-09-29 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
AU2017306711B2 (en) 2016-08-05 2022-08-04 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
CN109890415B (zh) 2016-08-05 2023-04-04 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN118662649A (zh) 2016-12-30 2024-09-20 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
CN116870144A (zh) 2017-01-31 2023-10-13 默沙东有限责任公司 制备多糖-蛋白缀合物的方法
CN110337307A (zh) * 2017-02-24 2019-10-15 默沙东公司 增强肺炎链球菌多糖-蛋白缀合物的免疫原性
US20200054740A1 (en) 2017-02-24 2020-02-20 Merck Sharp & Dohme Corp. Pneumococcal conjugate vaccine formulations
CN118356485A (zh) 2017-06-10 2024-07-19 创赏公司 提供改善的免疫原性和亲合力的具有二价或多价缀合物多糖的多价缀合物疫苗
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
ES2994040T3 (en) * 2017-09-07 2025-01-16 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CN116898959A (zh) 2017-09-07 2023-10-20 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
US11524076B2 (en) * 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
AU2018328038B2 (en) 2017-09-07 2024-03-07 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US10246715B1 (en) * 2017-10-02 2019-04-02 National Health Research Institutes CpG-oligodeoxynucleotide, immunogenic composition including the same, and method of inducing immune response by the same
KR102573200B1 (ko) 2017-12-06 2023-08-31 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질접합체를 포함하는 조성물 및 그의 사용 방법
JP7288451B2 (ja) 2018-02-05 2023-06-07 サノフィ パスツール インコーポレイティッド 多価肺炎球菌多糖体－タンパク質複合体組成物
MX2020008198A (es) 2018-02-05 2020-09-22 Sanofi Pasteur Inc Composicion del conjugado proteina-polisacarido multivalente neumococica.
CN111989114A (zh) 2018-04-18 2020-11-24 Sk生物科学株式会社 肺炎链球菌的荚膜多糖以及其免疫原性缀合物
WO2019212844A1 (en) 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
JP7506605B6 (ja) 2018-04-30 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌莢膜多糖類担体タンパク質複合体の製造方法
EP3787674A4 (en) 2018-04-30 2022-01-26 Merck Sharp & Dohme Corp. METHODS FOR PRODUCING CAPSULAR CARRIER PROTEIN-POLYSACCHARIDE CONJUGATES OF STREPTOCOCCUS PNEUMONIAE FROM LYOSPHERES
BR112020026899A2 (pt) * 2018-07-04 2021-03-30 Vaxcyte, Inc. Melhorias em conjugados imunogênicos
US20220016229A1 (en) * 2018-12-12 2022-01-20 Pfizer Inc. Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
CR20210333A (es) 2018-12-19 2021-08-18 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
JP2021132644A (ja) 2020-02-21 2021-09-13 ファイザー・インク 糖の精製
EP3892260A1 (en) * 2020-04-10 2021-10-13 Bayer Animal Health GmbH Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids
CA3191005A1 (en) 2020-08-10 2022-02-17 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
JP2023546446A (ja) 2020-10-22 2023-11-02 ファイザー・インク 細菌多糖を精製する方法
CA3200968A1 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3221075A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2023385908A1 (en) 2022-11-22 2025-05-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
DE68907045T2 (de) 1989-01-17 1993-12-02 Eniricerche Spa Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind.
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
US5371197A (en) * 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
US5769047A (en) 1991-12-23 1998-06-23 Zoche; Michael Engine with oil separator
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
AU4230493A (en) 1992-05-06 1993-11-29 President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
DK0616034T3 (da) 1993-03-05 2005-02-21 Wyeth Corp Plasmid til fremstilling af CRM-protein og diphtheria toxin
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
WO1998052581A1 (en) 1997-05-20 1998-11-26 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
CA2344740C (en) 1998-09-30 2011-11-22 American Cyanamid Company Mutant cholera holotoxin as an adjuvant
ES2322306T3 (es) 1998-12-21 2009-06-18 Medimmune, Inc. Proteinas de streptpcpccus pneumoniae y fragmentos inmunogenicos para vacunas.
DK1141306T3 (da) 1998-12-23 2008-08-18 Id Biomedical Corp Streptococcus-antigener
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
EP1162999B1 (en) * 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
EP1165796A2 (en) 1999-04-09 2002-01-02 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
CA2413450C (en) 2000-06-20 2014-02-18 Shire Biochem Inc. Streptococcus antigens
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
JP2005508143A (ja) 2001-06-07 2005-03-31 ワイス・ホールデイングス・コーポレーシヨン アジュバントとしてのコレラホロトキシンの突然変異形
MXPA03011133A (es) 2001-06-07 2004-12-06 Wyeth Corp Formas mutantes de holotoxina de colera como adyuvante.
EP1425040A2 (en) 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
AU2002351623A1 (en) 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
WO2004011027A1 (en) * 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
ES2295836T3 (es) 2003-03-13 2008-04-16 Glaxosmithkline Biologicals S.A. Procedimiento de purificacion de citolisina bacteriana.
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
EP2366403B1 (en) * 2003-08-06 2014-10-08 The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services Polysaccharide-protein conjugate vaccines
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
US20050118199A1 (en) * 2003-10-07 2005-06-02 Esser Mark T. Process for covalently conjugating polysaccharides to microspheres or biomolecules
WO2007026190A2 (en) 2004-07-18 2007-03-08 Csl Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP1868645B1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
BRPI0607026B1 (pt) 2005-04-08 2022-02-15 Wyeth Processos para redução do teor de proteína e preservação do teor de polissacarídeo capsular em um caldo de lisado celular de streptococcus pneumoniae complexo antes da purificação
PT1968631E (pt) * 2005-12-22 2015-07-20 Glaxosmithkline Biolog Sa Vacina
BRPI0715396B8 (pt) * 2006-08-07 2021-05-25 Harvard College método de produção de uma composição para vacina
AU2007307800C1 (en) 2006-10-10 2014-03-13 Wyeth Llc Purification of Streptococcus pneumoniae type 3 polysaccharides
US20100183667A1 (en) * 2006-10-12 2010-07-22 Glaxo Smithkline Biologicals S.A. Vaccine Comprising an Oil in Water Emulsion Adjuvant
ES2677353T3 (es) 2007-03-23 2018-08-01 Wyeth Llc Procedimiento abreviado de purificación para la producción de polisacáridos capsulares de Streptococcus pneumoniae
CN105267974A (zh) * 2007-06-20 2016-01-27 辉瑞爱尔兰制药公司 用于缀合疫苗的经过修饰的多糖
US9610340B2 (en) * 2007-06-26 2017-04-04 Glaxosmithkline Biologicals, S.A. Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates
RU2559525C2 (ru) * 2008-07-08 2015-08-10 Эббви Инк Белки, связывающие простагландин е2, и их применение
EP2424562B1 (en) 2009-04-30 2015-10-07 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
AU2011338723A1 (en) * 2010-12-10 2013-05-30 Merck Sharp & Dohme Corp. Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
GB201103836D0 (en) * 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
GB201106225D0 (en) * 2011-04-13 2011-05-25 Glaxosmithkline Biolog Sa Fermentation process
KR102057217B1 (ko) * 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
SI3421051T1 (sl) * 2012-08-16 2020-08-31 Pfizer Inc. Postopki in kompozicije glikokonjugacij
CA2884241C (en) * 2012-09-07 2018-11-20 Sk Chemicals Co., Ltd. Production method for capsular polysaccharide having pneumococcal serotype
US20140105927A1 (en) * 2012-10-17 2014-04-17 Glaxosmithkline Biologicals S.A. Immunogenic composition
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
GB201218660D0 (en) * 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
EP4169929A1 (en) * 2012-12-20 2023-04-26 Pfizer Inc. Immunogenic compositions comprising pn-serotype 12f
ITMI20130142A1 (it) * 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
MX386692B (es) * 2014-01-21 2025-03-19 Pfizer Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PE20161095A1 (es) * 2014-01-21 2016-10-26 Pfizer Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y uso de los mismos
CA2937184A1 (en) * 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
ES2701169T3 (es) * 2014-02-14 2019-02-21 Pfizer Conjugados glucoproteicos inmunogénicos
US9631328B2 (en) * 2014-03-12 2017-04-25 Permavoid Limited Sports field structure and modules and method for forming the same
CN107427568B (zh) * 2015-01-15 2021-12-14 辉瑞公司 用于肺炎球菌疫苗中的免疫原性组合物
MY182282A (en) * 2015-05-04 2021-01-18 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
PE20240927A1 (es) * 2015-07-21 2024-04-30 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
US10751402B2 (en) * 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
WO2018134693A1 (en) * 2017-01-20 2018-07-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN110337307A (zh) * 2017-02-24 2019-10-15 默沙东公司 增强肺炎链球菌多糖-蛋白缀合物的免疫原性
KR102783492B1 (ko) * 2017-09-07 2025-03-19 머크 샤프 앤드 돔 엘엘씨 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도
US11524076B2 (en) * 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
KR102573200B1 (ko) * 2017-12-06 2023-08-31 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질접합체를 포함하는 조성물 및 그의 사용 방법

Also Published As

Publication number Publication date
US11426456B2 (en) 2022-08-30
IL270760A (en) 2020-01-30
AU2015208820A1 (en) 2016-07-14
US10918708B2 (en) 2021-02-16
US20210023193A1 (en) 2021-01-28
KR20160108539A (ko) 2016-09-19
WO2015110940A3 (en) 2015-11-26
HRP20211337T1 (hr) 2021-11-26
AU2020204254A1 (en) 2020-07-16
EP3957321A3 (en) 2022-07-13
EP3096783A2 (en) 2016-11-30
IL283554A (en) 2021-07-29
RU2016126846A3 (ru) 2018-02-28
RU2710393C2 (ru) 2019-12-26
US20190000953A1 (en) 2019-01-03
JP2019163312A (ja) 2019-09-26
MX382438B (es) 2025-03-13
MX371454B (es) 2020-01-29
DK3096783T3 (da) 2021-08-02
ES2883343T3 (es) 2021-12-07
US10105431B2 (en) 2018-10-23
JP2020109072A (ja) 2020-07-16
PT3096783T (pt) 2021-08-16
IL270764B (en) 2021-04-29
EP3957321A2 (en) 2022-02-23
BR112016015835A2 (pt) 2017-09-19
PL3096783T3 (pl) 2021-12-13
JP6612260B2 (ja) 2019-11-27
US12343389B2 (en) 2025-07-01
JP2017504660A (ja) 2017-02-09
BR112016015835B1 (pt) 2023-12-26
EP3096783B1 (en) 2021-07-07
KR102049826B1 (ko) 2019-12-03
AU2015208820B2 (en) 2020-05-14
JP2020055810A (ja) 2020-04-09
CN112168957A (zh) 2021-01-05
IL270761B (en) 2021-04-29
HUE055408T2 (hu) 2021-12-28
IL270764A (en) 2020-01-30
SI3096783T1 (sl) 2021-09-30
KR20190132580A (ko) 2019-11-27
IL283554B (en) 2022-08-01
MX2016009468A (es) 2016-10-13
HK1223273A1 (zh) 2017-07-28
AU2020204254B2 (en) 2022-06-02
IL270761A (en) 2020-01-30
JP6594581B2 (ja) 2019-10-23
CN105934251A (zh) 2016-09-07
WO2015110940A2 (en) 2015-07-30
US20220378897A1 (en) 2022-12-01
CA2937184A1 (en) 2015-07-30
RU2016126846A (ru) 2018-02-28
FR22C1039I1 (fr) 2022-09-09
JP6947789B2 (ja) 2021-10-13
IL246652A0 (en) 2016-08-31
IL270760B (en) 2021-06-30
KR102099741B1 (ko) 2020-04-10
JP6947788B2 (ja) 2021-10-13
US20160324948A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
FR22C1039I2 (fr) Polysaccharides capsulaires de streptococcus pneumoniae et conjugués de ceux-ci
FR22C1041I2 (fr) Polysaccharides capsulaires de streptococcus pneumoniae et leurs conjugués
IL248961A0 (en) Oristatin histories and their conjugations
IL247344A0 (en) A new polysaccharide and its uses
LT3137114T (lt) Anti-ptk7 antikūnų ir vaistų konjugatai
PL3101032T3 (pl) Koniugat przeciwciało anty-HER2-lek
LT3126388T (lt) Antikūnai prieš egfrviii ir jų panaudojimo būdai
SG11201609490QA (en) Polymer-flavonoid conjugate and uses thereof
IL258759A (en) Anti-cd3-folate conjugates and their uses
EP3634981A4 (en) DESTREPTOCOCCUS PNEUMONIAE ANTIGEN COMPOSITIONS
HK40042634B (en) Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
TH1501007546A (th) ชิ้นส่วนปั๊มขึ้นรูปร้อนและวิธีการผลิตนั้น
TH1601003807A (th) คอนจูเกตของแอนติ-trop2 แอนติบอดี-ยา
ES1135587Y (es) Colchón atenuador de ronquidos